SCHEMBL6310096

SCHEMBL6310096

CCOC(=O)c1cccc2c1nc1c(C#N)c(C)c(-c3ccccc3)c(Cl)n12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.45
NPSR1 Q6W5P4 4/20 0.45
MAPT P10636 4/20 0.45
RAB9A P51151 4/20 0.45
LMNA P02545 3/20 0.45
NPC1 O15118 3/20 0.45
MDM2 Q00987 1/20 0.45
KDM4E B2RXH2 9/20 0.44
HSD17B10 Q99714 2/20 0.44
ALOX15 P16050 1/20 0.44
ALDH1A1 P00352 10/20 0.44
L3MBTL1 Q9Y468 5/20 0.44
PRF1 P14222 4/20 0.43
HPGD P15428 5/20 0.43
HTT P42858 3/20 0.43
KMT2A Q03164 2/20 0.43
HSP90AA1 P07900 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
MEN1 O00255 1/20 0.41
TDP1 Q9NUW8 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6311404 0.80 ALDH1A1 (0.39) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6310360 0.75 MAPT (0.67) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6310099 0.75 KDM4E (0.44) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6311577 0.74 SMN1; SMN2 (0.50) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6313411 0.72 LMNA (0.47) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6310907 0.71 KDM4E (0.49) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6319570 0.71 MAPT (0.46) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL5439361 0.70 ALDH1A1 (0.53) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6310448 0.70 HTT (0.41) SMN1; SMN2NPSR1MAPTRAB9ALMNA
SCHEMBL6311597 0.69 NPSR1 (0.52) SMN1; SMN2NPSR1MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 SMN1; SMN2 2642/4885NPSR1 1531/4885MAPT 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.